Lisa M. Rimsza, MD, a professor of pathology at the University of Arizona College of Medicine and a member of the Therapeutic Development scientific program at The University of Arizona Cancer Center, has been awarded $2.96 million from the National Cancer Institute to study molecular diagnosis and prognosis in aggressive lymphoma.
The project focuses on translating the previously discovery-oriented gene expression signatures into laboratory tests for lymphoma clinical trials and patient care.
The research consortium, the Lymphoma and Leukemia Molecular Profiling Project (LLMPP), will design and validate a multi-analyte diagnostic and prognostic gene signature assay to differentiate the five most common aggressive B cell non-Hodgkin lymphomas.
The LLMPP is uniquely posed to accomplish this work by virtue of having performed the "gold standard" GEP experiments that define the diagnostic and prognostic distinctions in these lymphomas as well as holding matching FFPET blocks from the same cases. Hence, this proposed research addresses a critical unmet need to translate previous advances in the molecular diagnosis of aggressive lymphomas into a new clinical paradigm for accurate diagnosis, prognosis, and therapeutic target identification.
February 24, 2012